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Abstract The MDM4 protein (also known as MDMX or
HDMX) is a negative regulator of p53, not only by direct
interaction but also through its interaction with MDM2.
Further, MDM4 overexpression and amplification have been
observed in several cancer forms. Recently, a single nucleo-
tide polymorphism (SNP) in the 3’ untranslated region of the
MDM4 gene, SNP34091A>C (rs4245739) was reported to
alter MDM4 messenger RNA (mRNA) stability by modulat-
ing a microRNA binding site, thereby leading to decreased
MDM4 levels. In this case-control study, we aimed to evaluate
the possible association between MDM4 SNP34091 status
and cancer risk by comparing the genotype frequencies in
large hospital-based cohorts of endometrial- (n=1404) and
ovarian (n=1385) cancer patients with healthy female con-
trols (n= 1870). Genotype frequencies were compared by
odds ratio (OR) estimates and Fisher exact tests. We found
that individuals harboring the MDM4 SNP34091AC/CC ge-
notypes had a significantly elevated risk for serous ovarian
cancer (SOC) in general and high-grade serous ovarian cancer
(HGSOC) in particular (SOC: OR=1.18., 95 % CI=1.01–
1.39; HGSOC: OR=1.25, CI = 1.02–1.53). No association
between SNP34091 genotypes and endometrial cancer risk
was observed. Our data indicate the MDM4 SNP34091AC/
CC genotypes to be associated with an elevated risk for SOC
and in particular the HGSOC type.
Keywords MDM4 . SNP34091 . Cancer risk . Ovarian
cancer . Endometrial cancer
Introduction
Maintaining the correct levels of p53 is imperative to cell
survival and normal tissue homeostasis, and thus, the p53
protein plays a pivotal role in cancer biology [1]. The protein
product of the murine double minute 2 gene, MDM2, and its
homologueMDM4 (also referred to asMDMX or HDMX) are
known to be the major negative regulators of p53 [2]. While
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both MDM2 and MDM4 inhibits p53 by direct binding and
masking of its transactivation domain [3–6], only MDM2
possesses E3 ubiquitin ligase activity and may downregulate
p53 by targeting it for ubiquitin-proteasome-dependent degra-
dation [7–9]. However, heterodimerization with MDM4 en-
hances MDM2’s E3 ligase activity towards p53 [10, 11].
Taken together, these data suggest that elevated levels of
MDM4 can prevent p53-mediated tumor suppression. In line
with this, the MDM4 gene has been found amplified and
overexpressed in several cancer forms (reviewed in [12]),
and studies in transgenic mice have shown that overexpres-
sion of Mdm4 induced spontaneous tumor formation and ac-
celerated tumorigenesis [13].
In the last decades, several single nucleotide polymor-
phisms in the MDM2 [14, 15] as well as the MDM4 [16–18]
loci have been associated with elevated or reduced cancer risk,
although data are at variance. Recently, a single nucleotide
polymorphism (SNP) in the MDM4 3’ untranslated region,
MDM4 SNP34091A>C (rs4245739) was reported to affect
MDM4 messenger RNA (mRNA) stability and protein levels
[19, 20]. The SNP34091C variant creates a functional target
site for hsa-miR-191, and both ovarian and prostate cancer
cells harboring the C- allele displayed reduced MDM4
mRNA and protein levels [19, 20].
Conflicting evidence has linked rs4245739 genotypes to
breast cancer risk. Thus, while case-control studies suggested
the SNP34091C-allele to be associated with a reduced risk for
breast cancer in general [17, 21] and among individuals car-
rying aMDM2 SNP309GG genotype in particular [17], recent
genome-wide association studies (GWAS) have reported the
C-allele to be associated with an increased risk for estrogen
receptor (ER) negative and, in particular, triple-negative breast
cancer [22–24]. Regarding other malignancies, the C-allele
has been associated with a reduced risk of non-Hodgkin lym-
phoma [25], esophageal squamous cell carcinoma [26], and
prostate cancer [27] but not with risk of cancer of the lung or
colon [17].
In this study, we assessed the impact ofMDM4 SNP34091




In this study, we successfully genotyped the MDM4
SNP34091A>C (rs4245739) status in endometrial cancer
samples (n = 1404) obtained from patients treated at
Haukeland University Hospital during 2001–2009 [28] and
from patients included in the MoMaTEC (Molecular
Markers in Treatment of Endometrial Cancer) study between
2007–2010 [29]. Further, we genotyped ovarian cancer
samples (n = 1385) from patients treated at the Oslo
University Hospital Radium Hospital in the period between
1993 and 2011 [15]. Notably, patients with known mutations
related to hereditary ovarian cancer (BRCA1 or BRCA2) were
excluded from the analysis.
For the endometrial cancer samples we had histological
and FIGO status for 1321 and 1238 patients, respectively.
As for the ovarian cancer, the grade of differentiation (high-
grade serous ovarian cancer (HGSOC), low-grade serous
ovarian cancer (LGSOC), clear cell ovarian cancer,
endometrioid ovarian cancer, and mucinous ovarian cancer)
was available for 1071 patients.
In order to evaluate OR for ovarian and endometrial cancer
related toMDM4 SNP34091 status, we compared our findings
to the SNP status among 1870 healthy controls. These were
the female fraction of a sample set of 3747 healthy individ-
uals, previously genotyped [17], and they were all obtained
from the population-based Cohort of Norway (CONOR)
study [30].
MDM4 SNP34091 genotyping
All samples were genotyped for MDM4 SNP34091 status
using a custom LightSNiP assay (TIB MOLBIOL
Syntheselabor GmbH, Berlin, Germany) on a LightCycler
480 II instrument (Roche, Basel, Switzerland) as previously
described in detail [17].
Statistical analysis
Potential deviations from Hardy-Weinberg equilibrium were
assessed by calculating the expected genotype distribution
based on the observed allele frequencies and comparing the
output with the observed genotype distribution using chi-
square tests.
Potential associations betweenMDM4 SNP34091 and risk
of ovarian and endometrial cancer as well as cancer risk within
different subgroups were estimated by calculating odds ratios
(OR) with 95 % confidence intervals (CI) and by Fisher’s
exact tests.
All statistical analyses were performed using the IBM
SPSS 22 software (IBM Corp, Armonk, NY, USA). p values
are given as two-sided and p values from Fisher’s exact tests
are given as cumulative.
Results
Distribution ofMDM4 SNP34091
Among the 1870 healthy female controls previously geno-
typed [17], we recorded a minor allele frequency (MAF) of
0.27. Regarding the present analyses, MDM4 SNP34091
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status was successfully genotyped in 1385 ovarian and 1404
endometrial cancers cases.
The genotype frequencies were found to be in Hardy-
Weinberg equilibrium (p>0.8 for all comparisons). A com-
prehensive overview of the MDM4 SNP34091 distribution in
the healthy controls as well as the two cancer types analyzed is
given in Table 1.
MDM4 SNP34091 status and cancer risk in ovarian cancer
In order to estimate the potential impact ofMDM4 SNP34091
status on ovarian cancer risk, we compared the frequency of
the MDM4 SNP34091 genotypes among ovarian cancer pa-
tients (n = 1385) to healthy female controls (n = 1870).
Although we observed no significant association between
MDM4 SNP34091 status and ovarian cancer risk, applying
the dominant model (SNP34091CC+AC vs. AA) we ob-
served a non-significant association with increased risk for
ovarian cancer (OR=1.12; 95 % CI=0.98–1.29; Table 1).
Following the observation of a potential association be-
tween the SNP34091CC/AC genotypes and increased risk of
ovarian cancer in general, we performed separate analyses for
the different subgroups of the disease with respect to histology
class and grade of differentiation. By doing so, we observed a
significant association between carriers of the SNP34091C
allele (dominant model) and increased risk of serous ovarian
cancer (OR=1.18; 95 % CI = 1.01–1.39), but not any in-
creased risk for clear cell, endometrioid, or mucinous ovarian
cancers (Table 2, Fig. 1). Further, by stratifying serous ovarian
carcinoma into the high-grade and low-grade type, we found
that the increased risk conferred by the SNP34091C allele was
highest in HGSOC (OR=1.25; 95 % CI=1.02–1.53; Table 2,
Fig. 1).
MDM4 SNP34091 status and cancer risk in endometrial
cancer
Comparing the genotypes of 1404 endometrial cancer patients
to the 1870 healthy controls, no association between MDM4
SNP34091 status and endometrial cancer were observed,
either by applying the dominant or the recessive model
(Table 1).
We further stratified the endometrial cancer patients ac-
cording to histological and FIGO status; however, no associ-
ation between SNP34091 genotypes and endometrial cancer
risk was observed in any of the subgroups (data not shown).
MDM4 SNP34091 and interaction withMDM2 SNP309
In the same sample set as analyzed in the present study, we
have previously reported the genotypes for the twomost wide-
ly studied functional SNPs in the MDM2 gene (MDM2
SNP285; rs117039649 and SNP309; rs2279744) [15, 28].
Since MDM4 and MDM2 act together in inhibiting the tumor
suppressor function of p53, we investigated potential
interactions/synergistic effects between MDM4 SNP34091
and MDM2 SNPs with respect to cancer risk.
Assessing ovarian cancer in general, we found a moderate
synergistic effect of SNPs in the two genes. However, when
restricting the analyses to HGSOC, we found particularly high
risk of disease among individuals with the MDM4
SNP34091C-allele and MDM2 SNP309TT genotype
(OR=1.41; 95 % CI=1.02–1.94; Supplementary Table S1).
In contrast, we found no synergistic effects between
MDM4 SNP34091 andMDM2 SNPs with respect to endome-
trial cancer risk (data not shown).
MDM4 expression levels in ovarian and endometrial cell
lines
Since we found an effect of MDM4 SNP34901 in ovarian—
but not endometrial cancer, we mined the publically available
data set from the Broad-Novartis Cancer Cell Line
En cy c l o p e d i a (CCLE–Bro a d I n s t i t u t e ; www.
broadinstitute.org/ccle/home). Comparing the available data,
we found the averageMDM4 expression level among ovarian
cancer cells (n=51) to be significantly lower than endometrial
cancer cells (n=27; p=0.003), indicating that ovarian cells
may be more sensitive to subtle changes inMDM4 levels than
endometrial cancer cells.
Table 1 MDM4 SNP34091 distribution and cancer risk
Cases/ Genotype OR (95 % CI) Fisher’s OR (95 % CI) Fisher’s
controls SNP34091 n (%) SNP34091 exact test SNP309 exact test
AA AC CC CC vs. AA+AC CC+AC vs. AA
Controls (females) 1021 (54.6) 703 (37.6) 146 (7.8) 1.00 – 1.00 –
Endometrial cancer 757 (53.9) 541 (38.5) 106 (7.6) 0.95 (0.74–1.25) 0.792 1.03 (0.90–1.18) 0.723
Ovarian cancer 716 (51.7) 564 (40.7) 105 (7.6) 0.97 (0.75–1.26) 0.842 1.12 (0.98–1.29) 0.102
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Discussion
In this study, we examined the association between theMDM4
SNP34091 status and ovarian- and endometrial cancer risk
applying a case-control design. This is, to the best of our
knowledge, the first case-control study estimating the effect
of MDM4 SNP34091 on risk for endometrial cancer and, al-
though a small study found an increased risk for relapse and
early onset of ovarian cancer among individuals carrying the
SNP34091A allele [20], no study has evaluated MDM4
SNP34091 status as a potential risk factor with respect to
ovarian cancer.
In our overall analyses, we observed no association be-
tween MDM4 SNP34091 status and the risk for endometrial
cancer, but a non-significant association between the
SNP34091C allele and an increased risk of ovarian cancer.
Notably, individuals carrying the SNP34091C allele had sig-
nificantly increased risk for developing serous ovarian cancer,
and in particular tumors of the HGSOC type, compared to
individuals harboring the SNP34091AA genotype. The risk
was particularly high among individuals carrying the MDM2
SNP309TT genotype. Although risk assessments are not di-
rectly comparable to survival analysis, our findings may seem
somewhat contradictory to the report of the SNP34091A allele
as a risk factor for recurrence and tumor-related death in ovar-
ian cancer patients [20]. While the SNP34091A allele has
been reported to confer higher MDM4 levels in ovarian [20]
and prostate cancer cells [19], and the common assumption is
that the oncogenic effect of high MDM4 levels is through the
p53 pathway [31], it has been reported that over 90 % of all
HGSOC have mutations in the TP53 gene [32]. Thus, it may
be that the effect ofMDM4 SNP34091 on ovarian cancer risk
is mediated via additional pathways, other than p53.
While evidence linking SNP34091 status to breast cancer
risk has been at variance [21–24], we recently found the
MDM4 SNP34091AC genotype to be associated with a re-
duced risk of breast cancer among individuals carrying the
MDM2 SNP309GG genotype [17], a genotype, in general,
associated with elevated cancer risk [33, 34]. In the same
study, no association between SNP34091 status and risk for
cancer of the lung, colon, or prostate was observed [17]. Our
findings in the present study are, however, in line with
Table 2 MDM4 SNP34091 and cancer risk in the histological OC types
Cases/ Genotype OR (95 % CI) Fisher’s OR (95 % CI) Fisher’s
controls SNP34091 n (%) SNP34091 exact test SNP309 exact test
AA AC CC CC vs. AA+AC CC+AC vs. AA
Controls (females) 1021 (54.6) 703 (37.6) 146 (7.8) 1.00 – 1.00 –
Serous (LG and HGSOC) 455 (50.4) 376 (41.6) 72 (8.0) 1.02 (0.76–1.37) 0.880 1.18 (1.01–1.39) 0.038
LGSOC 173 (49.7) 148 (42.5) 27 (7.8) 0.99 (0.65–1.52) 1.000 1.22 (0.97–1.53) 0.101
HGSOC 230 (49.0) 199 (42.4) 40 (8.5) 1.10 (0.76–1.59) 0.633 1.25 (1.02–1.53) 0.034
Clear cell (CC) 40 (59.7) 23 (34.3) 4 (6.0) 0.75 (0.27–2.09) 0.815 0.81 (0.50–1.33) 0.455
Endometrioid (E) 76 (57.6) 46 (34.9) 10 (7.6) 0.97 (0.50–1.89) 1.000 0.89 (0.62–1.27) 0.528
























Fig. 1 Impact of MDM4
SNP34091 on ovarian cancer risk.
Forest plot showing the effect of
SNP34091 in the different
histological ovarian cancer types
as compared to healthy female
controls. LGSOC low-grade
serous ovarian cancer, HGSOC
high-grade serous ovarian cancer
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previous studies reporting SNP34091C to be associated with
increased risk for triple-negative breast cancer [23, 24], a sub-
class of breast cancers sharing some mutational features with
HGSOC [35]. The tissue-specific effects observed are also in
line with the previously observed effect of the MDM2
SNP285G>C; where the C-allele is proposed to reduce the
risk for ovarian, endometrial, and breast cancer, but not cancer
of the prostate, lung, or colon [15, 28, 36, 37]. Notably, among
cell lines registered in Cancer Cell Line Encyclopedia
(CCLE–Broad Institute), we found a lower average MDM4
expression level among ovarian—than endometrial cancer
cells. One may, therefore, speculate that ovarian cells in gen-
eral are more sensitive than endometrial cells to subtle chang-
es in the MDM4 levels, such as those induced by the different
SNP34901 genotypes.
Previous candidate gene case-control studies assessing the
effect of the SNP34091 on cancer susceptibility has been per-
formed mainly in populations of Chinese ethnicity [21, 25,
26], and they have reported the SNP34091C-allele to be asso-
ciated with a reduced risk of cancer. Notably, there is a sub-
stantial difference in the distribution of this SNP between
Europeans and Asians with a MAF of 0.26 and 0.05, respec-
tively [38]. This is also the case for the MDM2 promoter
SNPs, SNP309, and SNP285: while the SNP309G allele is
associated with an increased cancer risk, predominantly,
among individuals of Asian ancestry [33, 34], the
SNP285C-allele, which is associatedwith reduced cancer risk,
[15, 28, 36], is absent in Asians and may therefore have a
confounding effect on SNP309 risk estimates performed in
Caucasian populations [39]. Thus, the somewhat variable re-
sults regardingMDM4 SNP34091 and cancer risk may also be
explained by yet unknown functional SNP (s) that are in link-
age disequilibrium (LD) with SNP34091.
A few years ago, Atwal and colleagues reported the
MDM4 haplotype diversity across ethnic populations.
They found a much greater diversity among individuals
of African American and Ashkenazi Jewish ancestry than
Caucasians ancestry. Further, they reported the SNP
rs1563828T allele, which is in LD with the SNP34091A
allele among Caucasians, to be associated with early onset
of both familial and sporadic ovarian cancer [16]. To the
best of our knowledge, the biological effects of SNP
rs1563828 have not been elucidated; thus, the possibility
exist that it may be SNP34091, which is known to have a
biological effect [19, 20], that contributes to the observed
effect of SNP rs1563828 previously reported by Atwal
and colleagues.
In conclusion, we find theMDM4 SNP34091 to be associ-
ated with increased risk of SOC, in particular the HGSOC
type, and in particular among individuals carrying the
MDM2 SNP309TT genotype. In contrast, no effect on endo-
metrial cancer risk was recorded. Although the observed ORs
are too low to argue for any clinical use ofMDM4 SNP status,
further studies are warranted in order to reveal whether it
could be a useful marker in any subgroup of cancers.
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